Premium
Dose determination for molecularly targeted therapies: Much Ado About Nothing
Author(s) -
Tolcher Anthony
Publication year - 2017
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.30584
Subject(s) - medicine , nothing , oncology , drug development , medical physics , drug , intensive care medicine , pharmacology , philosophy , epistemology
Literature reviews and meta‐analyses of phase 1 studies are particularly difficult to perform and rarely draw useful conclusions due to the small size of individual studies and the varied populations. With the low rate of success in oncology drug development, the focus should turn to improving the efficiency of phase 1 studies. See also pages 1409‐15.